Software Development Engineer 2 - iOS
About the job
- Bachelor's degree in computer science or a related field, or a master's degree in a technical discipline with 0–2 years of equivalent experience.
- A minimum of 2 years of native iOS application development experience using Swift.
- Three years of professional software development experience, or 2–5 years of related experience as typically required for the role.
- Experience working in Agile teams and using Jira and Confluence.
- Experience using continuous integration and continuous delivery tools such as Jenkins, Fastlane, GitHub Actions, and SonarQube.
- Experience with version control tools such as Git, GitHub, GitLab, Bitbucket, and GitFlow.
- Experience writing automated tests using XCTest, XCUITest, and Swift Testing.
- Working knowledge of design patterns such as Model–View–Controller, Model–View–ViewModel, and Model–View–Presenter.
- Experience developing software development kit layers.
- Experience working with the iOS operating system and multithreaded environments.
- Design and build applications for the iOS platform.
- Implement requirements in iOS applications and write and update design documents.
- Continuously discover, evaluate, and implement new technologies to strengthen development efficiency.
- Interface with software testing to ensure high-quality products.
- Develop automated unit and integration tests.
- Participate in design, code, and test reviews and provide technical leadership.
- Propose and implement enhancements to applications to improve sustainability.
About the company
Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1999
Get referred to Dexcom
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 13% to $1.308 billion, and guidance increased to $5.25 billion.
- Gross margin reached 64.1% in Q2 2026, helped by manufacturing efficiencies and 15-day conversion.
- Health2Sync expansion into Australia and Singapore broadens Dexcom's international digital-care distribution in 2026.
What critics are saying
- Dexcom faces 11 G7 and G6 lawsuits, including child hospitalizations, through October 2026.
- FDA classified 2026 G7 recalls for stolen scrap lots and watchOS software defects.
- Abbott still leads CGM share; a severe G7 trust failure threatens Dexcom's franchise.
What makes Dexcom unique
- Dexcom G7 15-day launched in 2025, lifting retention and margin economics in 2026.
- Dexcom secured G7 15-day clearance in Canada, expanding regulatory reach beyond the U.S.
- Dexcom pairs hardware with CLARITY and Health2Sync, building sticky diabetes workflow integration.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Remote Work Options
Flexible Work Hours
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Ransomware Group Redact hits: dexcom. HookPhish team Target organization DexCom dexcom.com Healthcare Summary. In the latest cybersecurity news, DexCom - an organization based in US - has fallen victim to a ransomware attack conducted by the group Redact. This data breach, discovered on Oct 10, 2026, 16:53 UTC, underscores the increasing need for proactive cybersecurity defenses as HookPhish continue through 2026. Incident report. | Target Organization | DexCom | | Threat Group | Redact | | Summary | Sector: Medical Equipment | Revenue: $4.97B USD | | Date of Breach | Oct 10, 2026, 16:53 UTC | | Discovery Date | Oct 10, 2026, 16:53 UTC | | Region | US | | Target Domain | dexcom.com | | Business Sector | Healthcare | How to reduce your ransomware risk. Most ransomware intrusions start with a stolen password or a phishing email. A few proactive steps sharply cut your exposure: * security awareness training - close the gap attackers exploit. * dark web monitoring - close the gap attackers exploit. Disclaimer. HookPhish does not engage in the exfiltration, downloading, taking, hosting, viewing, reposting, or disclosure of any stolen information. All breach data reported here is sourced from publicly available threat intelligence feeds for awareness purposes only.
DexCom Data Breach investigation. Migliaccio & Rathod LLP is investigating the possible DexCom Data Breach, impacting an unknown number of individuals and their personal information. What happened? On October 5, 2026, dark web monitoring sites reported that DexCom had been named as a victim of a data breach. Little information is available at this time regarding the nature of the breach or the data that may have been involved, but the affected information is believed to include sensitive and personal data. DexCom Data Breach. All of the information possibly stolen is likely valuable and dangerous to affected individuals. As seen in other cyberattacks, victims of data theft have reported identity theft attempts, fraudulent charges on bank or credit card accounts, unauthorized credit applications, misuse of medical or government services, exposure of information on the dark web, and a significant increase in spam calls, text messages, and emails. Are you concerned that you might be affected by the DexCom data breach? If you have concerns that your personal information may have been affected by this incident, and/or you have experienced suspicious activity recently, Migliaccio & Rathod LLP would like to hear from you. Please complete the contact form on this page, email Migliaccio & Rathod LLP at [email protected], or call Migliaccio & Rathod LLP at (202) 470-3520. The following will ask for your contact information so that Migliaccio & Rathod LLP may reach you to talk about potential claims. This information is for its records only and will not be shared. By continuing, you consent to the collection of this information for these limited purposes. Did you receive a notification that you were affected by the data breach? Would you like to join its newsletter to receive notifications about other investigations Migliaccio & Rathod LLP is looking into, as well as updates on ongoing cases? By submitting this form, you consent to receive marketing, updates, and informative SMS messages from Migliaccio & Rathod LLP at the email and/or phone number provided. Message & data rates may apply. Message frequency varies. Unsubscribe at any time by replying STOP or Reply HELP for help. Privacy Policy The lawyers at Migliaccio & Rathod LLP have years of experience in class action litigation against large corporations, including in cases involving data breaches such as this. More information about its current cases and investigations is available on its blog. To learn more about data breach litigation, you can listen here to the firm partners' explanation. Data Breach FAQ. I received a notice that my information may have been involved in a data breach. What should I do? If you receive a notification, take it seriously and read it carefully. It should identify what specific information may have been affected. Even if you believe your risk is minimal, it is best to take proactive steps to protect yourself. What immediate actions should I take? * Monitor your financial accounts - Regularly review your bank, credit card, and online accounts for unauthorized activity. * Change your passwords - Update passwords for any accounts that may be connected to the breach and avoid reusing passwords across platforms. * Enable two-factor authentication (2FA) - Use 2FA where available to add an additional layer of security. * Place a fraud alert or credit freeze - Contact Equifax, Experian, or TransUnion to help prevent unauthorized accounts from being opened in your name. What is credit monitoring, and how should I use it? Credit monitoring services watch for changes to your credit report and can alert you to potential fraudulent activity. If offered by a company at no cost, enrollment is strongly recommended. How long do I need to stay vigilant? The effects of a data breach can surface months or even years later. Remain alert for signs of identity theft for at least 12 to 24 months. Who can I contact if I need help? You can use the contact details provided in the breach notification. You can also report identity theft at www.identitytheft.gov for recovery resources. Migliaccio & Rathod LLP is here to be a resource to you. Fill out the contact form above to get in touch with Migliaccio & Rathod LLP.
Dexcom faces lawsuit alleging device failures endangered children. New lawsuits have been filed alleging Dexcom G7 glucose monitors malfunctioned, causing life-threatening emergencies in children, bringing total litigation to 11 cases. Claire Wallace, Senior Writer, Informa Markets - Engineering October 2, 2026 Morgan & Morgan has filed two additional lawsuits against Dexcom, Inc., alleging the company's G7 continuous glucose monitors malfunctioned and caused severe medical emergencies in children, bringing the firm's total litigation against the medical device manufacturer to 11 cases. The latest lawsuits involve a 7-year-old California girl and a 10-year-old Tennessee girl who were both hospitalized after their Dexcom G7 devices allegedly failed to accurately report blood glucose levels. The California lawsuit centers on a November 2025 incident in which a 7-year-old girl was hospitalized with profound diabetic ketoacidosis, a life-threatening complication that occurs when the body lacks sufficient insulin. According to the complaint, her Dexcom G7 malfunctioned and significantly misreported her glucose levels, preventing her family from recognizing that her blood sugar had reached dangerous levels. The Tennessee lawsuit involves a 10-year-old girl who was rushed to the hospital in August 2025 after her Dexcom G7 allegedly failed to alert her family that her blood sugar had dropped to dangerously low levels. By the time she arrived at the hospital, the lawsuit alleges her condition had deteriorated so severely that she experienced convulsive seizures requiring physical restraint by medical professionals. "Dexcom marketed this device as a safe and accurate replacement for finger sticks," said Morgan & Morgan founder John Morgan in a statement. "In doing so, they garnered the trust of parents of diabetic children who have come to depend on it to keep their children safe, but some of the devices allegedly did not work properly." Morgan & Morgan attorneys Shannon Pennock and Jack Rutherford emphasized the firm's commitment to accountability. "These lawsuits are about accountability," they said. "We want to ensure no one else is harmed by a device they depend on to survive." The firm has now filed 11 lawsuits against Dexcom involving both the G7 and earlier-generation G6 glucose monitors on behalf of plaintiffs across California, Florida, New Jersey, Tennessee, Kentucky, and Louisiana. Three cases involve minors, while four allege that Dexcom users died from medical events that plaintiffs contend could have been prevented had the devices functioned properly. The Dexcom G7 has also been subject to multiple recalls. The complaints were filed in the Superior Court of the State of California - County of San Diego, where Dexcom's global headquarters are located. The company is currently working on its next iteration, the Dexcom G8, despite a plethora of ongoing G7 concerns. Senior Writer, Informa Markets - Engineering Claire Wallace is a senior staff writer at Medical Device + Diagnostics Industry (MD+DI), where she covers key developments in the healthcare and medical device industry. With nearly a decade of journalism experience, she brings a deep understanding of the healthcare industry and a proven ability to connect with physicians, medtech leaders, and policy experts on the issues shaping care delivery today. She is committed to delivering nuanced coverage that helps industry professionals anticipate trends, understand regulatory shifts, and identify opportunities in an increasingly complex healthcare ecosystem. Before joining MD+DI, Claire spent three years at Becker's Healthcare as a writer and assistant editor, leading coverage on developments across orthopedics, outpatient care, cardiology, and gastroenterology that bridged perspectives from clinicians and healthcare executives. Her reporting background also includes lifestyle, political, and clean energy news, with bylines in various national and digital publications. Claire earned her bachelor's degree in Communications and Media & Screen Studies from Northeastern University, where she also minored in Political Science and Journalism. She holds a master's degree in Media Advocacy and is currently based in Chicago. Want more MD+DI in your search results?
Heidi rolls out AI agents and more briefs. Also, Dexcom and Health2Sync are extending their integrated CGM offering to Australia and Singapore. By Adam Ang | October 2, 2026 | 12:59 AM Heidi introduces AI agents Heidi has unveiled the latest version of its AI platform with AI agents that perform administrative tasks around patient visits. The upgraded platform features new AI agents that can plan and execute tasks such as pre-charting, referral communications, panel reviews and follow-up work across EHRs, calendars, inboxes and patient portals. Heidi maintained that clinicians retain approval and control over decision-making. Heidi II rollout began in late September in English and French outside the United Kingdom and European Union. Dexcom, Health2Sync expand APAC integration CGM maker Dexcom and Taipei-based Health2Sync are expanding their diabetes technology partnership to Australia and Singapore, extending an existing collaboration in Japan. The collaboration offers Health2Sync's digital platform that can be integrated with Dexcom's continuous glucose monitoring (CGM) data. The integrated offering will go live in the "next few months," Dexcom said in a LinkedIn post. Qld AI launchpad bags fed grant Queensland University of Technology (QUT) researchers have received an A$1.49 million (about $1 million) federal government grant to develop and evaluate AI launchpads intended to help health services implement and sustain AI in routine care. According to a media release, the project will work with clinicians, consumers, digital health researchers and industry to build local systems and workforce capabilities for procuring proprietary AI, adapting tools from other health services and developing and evaluating AI within health service environments. Partners include health services: Metro South, Children's Health Queensland, Sunshine Coast, West Moreton, Mackay, Queensland Health, as well as Microsoft Australia and the Australian Institute of Digital Health.
Dexcom promotes Jereme Sylvain to Chief Operating Officer. Key Takeaway: Dexcom has announced the promotion of Jereme Sylvain to Chief Operating Officer. This strategic move is expected to bolster the company's operational capabilities and drive future growth. Sylvain's leadership is anticipated to play a crucial role in advancing Dexcom's objectives. Market sentiment analysis. Positive factors. * Jereme Sylvain's promotion reflects confidence in leadership. * The move may enhance operational efficiency at Dexcom. * This change could positively impact company direction. SAN DIEGO-(BUSINESS wire)-dexcom promotes Jereme Sylvain to Chief Operating Officer. Frequently asked questions. Who was promoted to Chief Operating Officer at Dexcom? Jereme Sylvain has been promoted to Chief Operating Officer at Dexcom. What is the significance of Jereme Sylvain's promotion? His promotion is expected to enhance operational efficiency and company growth.